Ipamorelin vs Pasireotide
Overview
Ipamorelin is primarily a performance & growth peptide, while Pasireotide is used for hormonal.
This page compares Ipamorelin and Pasireotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Ipamorelin | Pasireotide | |
|---|---|---|
| Category | Performance & Growth | Hormonal |
| Regulatory status (US) | Research use only | FDA approved |
| Typical dosage | 200-300 mcg | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) |
| Frequency | twice-daily | Twice daily (SC formulation) or every 4 weeks (LAR formulation) |
| Reported benefits | Natural GH release, improved body composition, better sleep, anti-aging effects, no appetite increase | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism |
| Reported side effects | Very well-tolerated. Rare: headache, injection site reactions | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) |
Key differences
Primary use. Ipamorelin is categorised under Performance & Growth, while Pasireotide falls under Hormonal. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Ipamorelin: not FDA-approved; treated as a research compound. Pasireotide: FDA-approved.
Dosing. Ipamorelin is typically dosed at 200-300 mcg (twice-daily). Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)).
Can you stack them?
Some protocols combine peptides, but stacking Ipamorelin and Pasireotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Ipamorelin and Pasireotide?
- Ipamorelin is primarily a performance & growth peptide, while Pasireotide is used for hormonal. Ipamorelin is not FDA-approved; generally classified as a research compound, whereas Pasireotide is FDA-approved for one or more indications.
- What is Ipamorelin used for?
- GH secretagogue, anti-aging.
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- Can you take Ipamorelin and Pasireotide together?
- Some users combine peptides within a single protocol, but stacking Ipamorelin and Pasireotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Ipamorelin or Pasireotide FDA-approved?
- Ipamorelin is not FDA-approved; generally classified as a research compound. Pasireotide is FDA-approved for one or more indications.
Read the full articles
- Ipamorelin — full monograph: mechanism, research, dosing & references
- Pasireotide — full monograph: mechanism, research, dosing & references